Week 4 viral response to peginterferon and ribavirin: How should it be used in combination with a baseline predictive factor?  by Toyoda, Hidenori et al.
Week 4 viral response to peginterferon and ribavirin: How should
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the IL28B gene (rs12979860), although they focused on patients
with RVR and did not include patients with non-RVR but with a
P3log10 drop at week 4. This discrepancy between their study
and ours may be partly explained by the difference in the eth-
nicity of the study population. The study by Thompson et al.
was based on patients from the IDEAL study including Cauca-
sians, African Americans, and Hispanics, whereas all patients
were Japanese Asians in our study. Similarly, the ethnicity
was different between the population studied by Marcellin et
al. and ours. Accordingly, the distribution of rs12979860 or
rs8099917 genotypes and the rate of concordance between
rs12979860 (analyzed in a study by Thompson et al.) and
rs8099917 (analyzed in our study) would be different. For
example, the rate of favorable homozygote (CC rs12979860
genotype and TT rs8099917 genotype) was largely different:
33.0% in Thompson’s study and 76.1% in our study. Moreover,
our study involved only patients infected with HCV genotype
1b. These factors should be adjusted when comparing the asso-
ciation between the genetic polymorphisms near the IL28B gene
and the predictive value of week 4 viral response between stud-
ies. Nonetheless, the genetic polymorphism near the IL28B gene
appears to have a strong impact on the predictive value of early
viral response to therapy; the prediction of SVR by week 4 viral
response may have to be modiﬁed based on this strong baseline
predictive factor.
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We read with great interest the article by Marcellin et al. [1] eval-
uating the predictive value of week 4 viral response to peginter-
feron-alpha 2a and ribavirin combination therapy in patients
with hepatitis C virus (HCV) genotype 1. They concluded that
patients with a P3log10 drop in HCV RNA at week 4 have a high
probability of achieving sustained virologic response (SVR),
which is consistent with our previous study [2].
Previous studies reported that the genetic polymorphism near
the interleukin 28B (IL28B) gene (rs12979860 or rs8099917) is a
strong baseline factor associated with the outcome of therapy [3].
However, this variable was not included in the study by Marcellin
et al., probably because the actual treatment period in the study
predated this ﬁnding [4,5]. Given these predictors, i.e. week 4
viral response and a baseline variable, how should they be com-
bined to predict response?
We evaluated the predictive value of week 4 viral response to
combination therapy on SVR in 272 patients infected with HCV
genotype 1b [6]. Overall, a P3log10 drop in HCV RNA at week 4
was a strong predictor of SVR. SVR was achieved in 77.0% of
patients with rapid virologic response (RVR) or a P3log10 drop,
whereas only 16.7% of patients with a <3log10 drop achieved
SVR (p <0.0001). When patients were stratiﬁed based on the
IL28B genetic polymorphism rs8099917, which corresponds to
rs12979860 in more than 99% of Japanese ethnicity [7], a
P3log10 drop at week 4 was strongly predictive of SVR in
patients with the favorable TT rs8099917 genotype (CC
rs12979860 genotype). The SVR rate was 79.5% in patients with
RVR or aP3log10 drop and 15.6% in patients with a <3log10 drop
(p <0.0001). In contrast, among patients with an unfavorable
TG/GG rs8099917 genotype, no differences were found in the
SVR rate between patients with RVR or a P3log10 drop (20.0%)
and those with a <3log10 drop (18.3%, p = 0.9265); the predictive
value of week 4 response is low in this subset. In addition, the
predictive value of complete early virologic response (EVR) for
SVR is lower in patients with the unfavorable TG/GG genotype.
The SVR rate was 81.6% in patients with complete EVR and
21.2% in patients without (p <0.0001), when patients had the
favorable TT rs8099917 genotype. In contrast, the rate of SVR
was 25.0% in patients with complete EVR and 18.0% in patients
without (p = 0.7279), when patients had the unfavorable TG/GG
genotype. Therefore, it appears to be difﬁcult to identify patients
with the unfavorable genotype of the genetic polymorphism
near the IL28B gene who have a likelihood to achieve SVR by
week 4 viral response, although it can identify patients with a
high likelihood of achieving SVR in patients with the favorable
genotype.
In contrast to our results, a previous large study by Thomp-
son et al. [8] reported that patients who attained RVR showed
high SVR rate regardless of the genetic polymorphisms nearJournal of Hepatology 2012 vol. 57 j 921–934 927
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Encephalopathy or hepatic encephalopathy?
These are clinical criteria and they are described, although not
in their exact, original form [5], in columns 2 and 3 of the table.
However, the table also depicts stages, characterized by paral-
lel alterations in consciousness, cognitive/behavioural features,
neurological ﬁndings, and electroencephalographic changes. Such
correspondence has never been established, which is the reason
why Conn and co-workers proposed the use of an index, not
unlike the Child–Pugh score, combining the independent scores
of ﬁve dimensions (mental state based on theWest Haven criteria,
Trail Making Test A, asterixis, electroencephalographic slowing
and arterial ammonia levels) [5]. In addition, the classiﬁcation of
electroencephalographic changes reported in column 5 of the
table does not correspond to either the one proposed by Conn
et al. [5] or to more modern ones [6], most likely in relation to a
typo or an alignment problem. An errata corrige on the involun-
tarily misleading information provided in Table 2 of the paper
might be necessary.
Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
References
[1] Gines P, Fernandez J, Durand F, Saliba F. Management of critically-ill cirrhotic
patients. J Hepatol 2012;56:S13–S24.
[2] Watanabe A. Portal-systemic encephalopathy in non-cirrhotic patients:
classiﬁcation of clinical types, diagnosis and treatment. J Gastroenterol
Hepatol 2000;15:969–979.
[3] Montagnese S, Biancardi A, Schiff S, Carraro P, Carla V, Mannaioni G, et al.
Different biochemical correlates for different neuropsychiatric abnormalities
in patients with cirrhosis. Hepatology 2011;53:558–566.
[4] van den Boogaard M, Pickkers P, Slooter AJ, Kuiper MA, Spronk PE, van der
Voort PH, et al. Development and validation of PRE-DELIRIC (PREdiction of
DELIRium in ICu patients) delirium prediction model for intensive care
patients: observational multicentre study. BMJ 2012;344:e420.
[5] Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, et al.
Comparison of lactulose and neomycin in the treatment of chronic portal-
Letters to the EditorTo the Editor:
We read with interest the paper by Ginès and co-authors on the
management of critically-ill cirrhotic patients [1]. However, we
have some concerns on the section on management of hepatic
encephalopathy. The authors seem to base their recommenda-
tions on a ‘statistical’ rather than a pathophysiological deﬁnition
of the syndrome, grouping under the heading ‘severe hepatic
encephalopathy’ a set of different neuropsychiatric symptoms
arising in critically-ill cirrhotic patients, to include mental abnor-
malities relating to sepsis, electrolyte imbalance, and even the
side- or desired-effects of drugs such as opioids and benzodiaze-
pines. Within this frame, they state that ammonia levels should
not be measured, as they provide no clinical information nor do
they relate to clinical outcomes. While we agree with the authors
that patients with cirrhosis, especially if critically-ill, may present
with more than one metabolic encephalopathy, and these may all
contribute and worsen the clinical picture, it seems to us that an
effort should be made to differentiate hepatic encephalopathy
from other forms of metabolic/toxic neuropsychiatric distur-
bance. For example, we need to be reasonably sure that the
encephalopathy we refer to in order to deﬁne fulminant hepatic
failure is hepatic encephalopathy, as we would not want to list
for transplant a patient with hepatitis who is confused because
of hypoglycaemia, or opioid/benzodiazepine overdose. In this
respect, ammonia levels seem useful, as they reﬂect hepatic fail-
ure and portal-systemic shunting [2], they correlate with recogni-
sed, quantiﬁed indices of hepatic encephalopathy, and they
predict the development of hepatic encephalopathy over time
[3]. Notably, sepsis, electrolyte imbalance, and psychoactive drugs
cause neuropsychiatric abnormalities in critically-ill patients with
no liver dysfunction [4]: we would not diagnose these patients
with hepatic encephalopathy, we would not expect them to be
hyperammonaemic and we would not treat them with ammo-
nia-lowering drugs such as non-absorbable disaccharides/antibi-
otics. Critically-ill cirrhotic patients are no exception. Should
they present with more than one potential cause for neuropsychi-
atric dysfunction, each cause should be identiﬁed and treated
according to its pathophysiology. Finally, there seems to be some
confusion in Table 2, in relation to the West Haven criteria [5].928 Journal of Hepatology 2012 vol. 57 j 921–934
